Patient Controlled Subcutaneous Analgesia of Hydromorphone Versus Morphine to Treat Moderate and Severe Cancer Pain: A Randomized Double-Blind Controlled Trial
Xianzheng Zeng,Jiang Zhu,Jun Li,Chan Chen,Ling Sang,Maotong Liu,Li Song,Hui Liu
DOI: https://doi.org/10.1016/j.jpainsymman.2023.09.018
IF: 5.576
2023-09-24
Journal of Pain and Symptom Management
Abstract:Context Hydromorphone and morphine are the common drugs used for the treatment of moderate to severe cancer pain. Patient controlled subcutaneous analgesia (PCSA) is an effective technique to manage cancer pain. However, few studies have been conducted to show the efficacy and safety of PCSA of hydromorphone for the relief of cancer pain. Objectives To explore the short-term efficacy and safety of PCSA elicited by hydromorphone for moderate to severe cancer pain. Methods This was a single-center, randomized, active-controlled, double-blind trial (from April 2019 to August 2021). Sixty patients with moderate to severe cancer pain were randomized (1:1) to hydromorphone or morphine groups according to drug delivery by PCSA. The primary outcome was the pain intensity measured by a numerical rating scale (NRS) at 72 h. Secondary outcomes included pain intensity measured by NRS at baseline, 15 min, 30 min, 2 h, 8 h, 24 h and 48 h. The daily occurrence of breakthrough pain (BTP), impact of pain on quality of life measured by the brief pain inventory (BPI), the daily additional consumption of opioids and the incidence of adverse events were also recorded. Adverse events included nausea, vomiting, dizziness, constipation and respiratory depression. Results A total of 57 patients (28 patients in the hydromorphone group and 29 patients in the morphine group) in the West China Hospital of Sichuan University were investigated. The mean (standard deviation [SD]) NRS in the two groups at baseline was 7.8 (1.7) in the hydromorphone group and 7.6 (1.7) in the morphine group, and at 72 h were 3.4 (1.8) and 3.2 (1.5), respectively. The postoperative NRS in both groups was decreased significantly compared to baseline. The mean (SD) NRS at 30 min in the hydromorphone group was significantly lower than in the morphine group (3.9 (2.6) vs. 5.3 (2.1), P = 0.035). The daily occurrence of BTP in both groups at 48 h and 72 h decreased significantly compared to the corresponding baseline ( P < 0.05), and there was no significant difference between the two groups. The total scores and sub-item scores of BPI at 24 h and 72 h after PCSA in both groups decreased significantly from baseline. A comparison of daily additional consumption of opioids between the two groups revealed no statistically significant difference. There were no significant differences in the incidences of nausea, vomiting, dizziness or constipation between the two groups ( P > 0.05). Conclusions This study found that the PCSA of both hydromorphone and morphine could effectively and safely relieve short-term moderate to severe cancer pain. Of note, the PCSA of hydromorphone took effect more quickly than that of morphine.
medicine, general & internal,clinical neurology,health care sciences & services